000164021 001__ 164021
000164021 005__ 20240313115344.0
000164021 0247_ $$2doi$$a10.1007/s00115-022-01294-2
000164021 0247_ $$2pmid$$apmid:35552466
000164021 0247_ $$2pmc$$apmc:PMC9096778
000164021 0247_ $$2ISSN$$a0028-2804
000164021 0247_ $$2ISSN$$a1433-0407
000164021 0247_ $$2altmetric$$aaltmetric:128238791
000164021 037__ $$aDZNE-2022-00684
000164021 041__ $$aGerman
000164021 082__ $$a610
000164021 1001_ $$aGerhard, Ameli$$b0
000164021 245__ $$aManifestationen im Zentralnervensystem nach COVID-19.
000164021 260__ $$aHeidelberg$$bSpringer$$c2022
000164021 3367_ $$2DRIVER$$aarticle
000164021 3367_ $$2DataCite$$aOutput Types/Journal article
000164021 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661509180_607$$xReview Article
000164021 3367_ $$2BibTeX$$aARTICLE
000164021 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164021 3367_ $$00$$2EndNote$$aJournal Article
000164021 500__ $$aCC BY: https://creativecommons.org/licenses/by/4.0/
000164021 520__ $$aNumerous diseases of the central nervous system (CNS), especially in the postacute phase after an infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been described. These include neuroimmunologically mediated diseases, such as encephalopathy, encephalitis, myelitis, acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis (ANHLE) and neuromyelitis optica spectrum disorder (NMOSD) as well as others, such as posterior reversible encephalopathy syndrome (PRES), opsoclonus myoclonus ataxia (OMA) and cerebrovascular diseases. A parainfectious or postinfectious association is discussed but the pathophysiological mechanisms are so far unknown. Underlying mechanisms could be a virus-triggered overactivation of the immune system with hyperinflammation and cytokine storm but possibly also the development of specific autoantibodies against CNS tissue. Direct damage due to the invasion of SARS-CoV‑2 into the brain or spinal cord does not seem to play a relevant role. An exact clinical phenotyping and initiation of additional diagnostics are recommended, also to rule out other causes. To date no medicinal treatment options for CNS manifestations of long COVID exist; however, first results regarding inflammation and autoimmunity are promising and could lead to new treatment approaches.
000164021 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164021 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164021 650_7 $$2Other$$aAutoantibodies
000164021 650_7 $$2Other$$aEncephalitis
000164021 650_7 $$2Other$$aHyperinflammation
000164021 650_7 $$2Other$$aImmunotherapy
000164021 650_7 $$2Other$$aMyelitis
000164021 650_2 $$2MeSH$$aCOVID-19: complications
000164021 650_2 $$2MeSH$$aCentral Nervous System
000164021 650_2 $$2MeSH$$aHumans
000164021 650_2 $$2MeSH$$aNervous System Diseases: etiology
000164021 650_2 $$2MeSH$$aPosterior Leukoencephalopathy Syndrome
000164021 650_2 $$2MeSH$$aSARS-CoV-2
000164021 650_2 $$2MeSH$$aPost-Acute COVID-19 Syndrome
000164021 7001_ $$0P:(DE-2719)2810931$$aPrüß, Harald$$b1$$udzne
000164021 7001_ $$0P:(DE-2719)2811159$$aFranke, Christiana$$b2$$udzne
000164021 773__ $$0PERI:(DE-600)1462945-8$$a10.1007/s00115-022-01294-2$$n8$$p769-778$$tDer Nervenarzt$$v93$$x0028-2804$$y2022
000164021 8564_ $$uhttps://pub.dzne.de/record/164021/files/DZNE-2022-00684.pdf$$yOpenAccess
000164021 8564_ $$uhttps://pub.dzne.de/record/164021/files/DZNE-2022-00684.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000164021 909CO $$ooai:pub.dzne.de:164021$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000164021 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000164021 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811159$$aExternal Institute$$b2$$kExtern
000164021 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164021 9141_ $$y2022
000164021 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000164021 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000164021 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000164021 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000164021 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000164021 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000164021 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNERVENARZT : 2021$$d2022-11-12
000164021 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000164021 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-28$$wger
000164021 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000164021 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000164021 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000164021 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-12
000164021 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000164021 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000164021 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000164021 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Enzephalopathies$$x0
000164021 980__ $$ajournal
000164021 980__ $$aVDB
000164021 980__ $$aUNRESTRICTED
000164021 980__ $$aI:(DE-2719)1810003
000164021 9801_ $$aFullTexts